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Abstract
Background:Histologic prognostic factors have been described for nodular lymphocyte predomi-
nantHodgkin lymphoma (NLPHL). This studyexamineshistologic and immunophenotypic variants
in a clinical trial for pediatric NLPHL.
Procedure:One hundred sixty-eight cases of localized NLPHL were examined for histologic vari-
ants, CD30 and immunoglobulin D (IgD) expression, and outcome. Histologic types were scored
categorically as 0= 0, 1≤ 25%, and 2> 25% of the sample.
Results: Fifty-eight (35.1%) cases showed only typical nodular with or without serpiginous histol-
ogy (types A and B). The remainder showedmixtures of histologies. The numbers of patients with
score 2 are 85 (50.6%) type A, 21 (12.5%) type B, 46 (27.4%) with extranodular large B cells (type
C), 3 with T-cell-rich nodular pattern (type D), 55 (32.7%) with diffuse T-cell-rich (type E) pattern,
and 2 (1.2%) with diffuse B-cell pattern (type F). Higher level of types C (P = 0.048) and D (P =
0.033) resulted in lower event-free survival (EFS). Cytoplasmic IgDwas found in 65 of 130 tested
(50%), did not significantly associate with EFS but positively correlated with types C and E histol-
ogy (P< 0.0001) and negatively correlatedwith types A (P= 0.0003) and B (P= 0.006). Seventeen
(10%) expressed CD30, with no adverse effect.
Conclusions:Variant histology is common in pediatric NLPHL, especially types C and E, which are
associated with IgD expression. Type C variant histology and possibly type D are associated with
decreased EFS, but neither IgD nor CD30 are adverse features. Variant histology may warrant
increased surveillance, but did not affect overall survival.
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1 INTRODUCTION
Nodular lymphocyte predominant (LP) Hodgkin lymphoma (NLPHL)
represents 5–10% of Hodgkin lymphoma (HL) with a male pre-
dominance and typical presentation of low-stage disease without B
symptoms. NLPHL is usually slow-growing and responsive to therapy,
but may bemore aggressive.1
Children’s Oncology Group trial AHOD03P1 was designed to test
the efficacy of stage-directed reduced-therapy treatment of low-risk
NLPHL in young people, with stage IA or IIA disease.1 At the time of
protocol design, there had been recent reports of a relatively new sub-
type of classical HL (CHL) mimicking NLPHL, lymphocyte-rich CHL.2
These were noted in one large series to constitute about 34% of cases
previously diagnosed as NLPHL.3
The protocol was designed with a “watch and wait” component
for totally resected stage IA disease present in a single node. Out of
concern that this would not be appropriate for CHL, all cases were
required to have immunohistochemical (IHC) staining performed, and
all were subjected to rapid pathology review.
The morphology and immunohistochemistry of NLPHL show nod-
ules of small B cells with admixed larger neoplastic LP cells (Fig. 1A).4,5
F IGURE 1 Histology and immunophenotype of typical nodular lym-
phocyte predominant Hodgkin lymphoma. (A) Scattered large LP cells
are present, along with a few histiocytes, in a nodule of small B cells
in typical NLPHL. The inset shows B-cell marker CD20 antibody label-
ing both small and large cells. (B) Small T cells labeled with anti-CD3
(illustrated here) and oftenCD57 form rosettes around the LP cells. (C)
Nodules of small lymphocytes with admixed LP cells and histiocytes in
typical type A histology. (D) CD20 shows the B-cell nature of nodules.
(E) Some cases show a serpiginous growth pattern in type BNLPHL. (F)
CD20 labels both small B cells and LP cells in serpiginous areas of type
BNLPHL
(LP cells are also sometimes referred to as lymphocytic and histio-
cytic (L&H) cells, from an earlier name of lymphocytic and histiocytic
HL.) LP cells are mature B cells that label positively for CD20, CD45,
B-cell transcription factors OCT2 and BOB1, and immunoglobulin J-
chain. They are usually negative for both CD30 and CD15 (in con-
trast to classical Hodgkin–Reed–Sternberg cells that are typically pos-
itive for both). T cells often rosette around the large cells (Fig. 1B)
and CD57/CD4-positive T cells may be increased in the nodules, while
other T cells predominate in the internodular areas.
Morphologic patterns have been described to include classic
morphology (nodular or serpiginous, type A or B), as well as several
categories of variant histology, including those with prominent extra-
nodular LP cells (pattern C), T-cell-rich nodules (pattern D), diffuse
T-cell-rich (T-cell-rich large B-cell lymphoma like, pattern E) and
diffuse B-cell-rich patterns (moth-eaten, pattern F).6 Variant histology
has been incorporated into novel grading schemes for NLPHL as it has
been tentatively associated with adverse features.7–10
Positivity for CD30 has been noted in up to 28% of NLPHL, usually
focal or heterogeneous andmore frequent in the presence of Epstein–
Barr virus (EBV).11–14 CD30 may provide a target for anti-CD30 ther-
apeutic antibodies in the rare CD30-positive cases that relapse.15
IgD expression has been described to be frequent in young male
patients and to be associated with the presence of large B cells in the
extranodular regions.7,16 In this study we examine the histologic pat-
terns, CD30 and IgD expression of NLPHL, and compare them relative
to patient outcomes in the context of a single pediatric clinical trial.
1.1 Patients andmethods
1.1.1 Patient group
Patients were those enrolled in a nonrandomized clinical trial (study
AHOD03P1) for low-risk NLPHL conducted at Children’s Oncology
Group institutions from January 2006 through November 2010 (Clini-
calTrials.gov IdentifierNCT00107198).Written informed consentwas
obtained according to institutional guidelines and in compliance with
Declaration of Helsinki guidelines. Eligible patients were less than
22 years of age with stage IA/IIA NLPHL. Patients with B symptoms
or bulky disease were excluded from the study.
1.1.2 Histology
Stained and unstained slides from fixed, paraffin-embedded lymph
node biopsies were histologically reviewed and assessed according to
histologic pattern, and according toCD20,CD30, and IgD immunophe-
notype of the neoplastic LP cells. CD20 and CD30 were performed
prospectively at treating institutions and were required for entry on
the protocol. Protocol guidelines also recommended a minimum anti-
body panel of CD45, CD3 (orCD45Ro), CD20, CD15, CD30, and kappa
and lambda immunoglobulins,with optional recommendationofCD57,
BOB.1, EMA, CD79a, BCL6, CD68, Oct2, ALK-1, and J-chain. CD21
and/or CD23 were scored in some cases, although not stressed for
diagnosis at the time of protocol design. Most cases had been vetted
by expert hematopathologists prior to enrollment in the study. All sub-
mitted slideswere reviewedprospectively anddiagnoses confirmedon
enrollment in a rapid review.
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Submitted CD30 stains were examined, staining of all cases
described as positive at the treating institutionwas repeated, and addi-
tionally was repeated for all other cases with unstained slides. Final
scoring of CD30 was based on our review of one or more slides. For
most cases, CD20 stainingwas also repeated. IgDwas performedon all
cases that had available unstained slides. Repeat IHC stains were per-
formed on an automated immunostainer (Ventana Medical Systems,
Tucson AZ), with monoclonal antibodies CD30, CD20, CD3, and anti-
IgD (Cell Marque, Rocklin, CA) using standard technique.
All cases were categorized based on morphology into five cate-
gories, corresponding to the patterns reported by Fan et al.6 Each
case was assessed for percent involvement by each histologic type,
and then condensed to a score of 0–2 as described in the statistical
section.
1.1.3 Treatment strategy
Patients with stage I disease and total resection of a single involved
node were observed without further therapy; recurrences were
treated with three cycles of AV-PC (doxorubicin/vincristine/
prednisone/cyclophosphamide). Patients with unresected stage
IA or stage IIA were treated with three cycles of AV-PC. Patients
with less than a complete response (CR) to AV-PC received 21 Gy
involved-field radiation therapy.1
1.1.4 Statistics
For each histologic type, A–E, the proportion of involvement of avail-
able sample was scored 0–2: 0 = 0, 1 < 25%, 2 > 25% for variant his-
tology. CD30 and IgD expression was divided into two groups based
on the groupings (yes/no). Statistical inference (Chi-square test on
categorical variables and t-test on continuous variables) was per-
formed to compare the demographics between groups. The event-free
survival (EFS) curves were compared among the three levels of each
variant histology, and between the two levels of CD30 and IgD expres-
sion by log-rank tests. Polychoric or tetrachoric correlations were also
measured among variant histology, CD30 and IgD expression.
2 RESULTS
Details of patient characteristics, therapy, andoverall clinical outcomes
have been previously reported.1 Briefly, 188 patients were enrolled,
183 were eligible, and 178 were evaluable for analysis in the clini-
cal report of this protocol; 5 patients who had protocol deviations
were excluded. Among these, 168 cases were available for further
histopathologic evaluation at theendof protocol (slideswereno longer
available in 10 cases). The mean age at enrollment was 12.3 years
(range 4.2–20.7), and 85% were males. The most common sites of
involvement were lymph node groups in the head and neck, axilla, or
groin. Mediastinal involvement was rare (n = 7, 3.8%). A diagnosis of
NLPHL was confirmed by central review for each case. EFS at 5 years
was 85.5% and overall survival (OS) at 5 years was 100%.
Fifty-nine (35.1 %) cases showed only typical nodular or nodular
and serpiginous histology (types A and B; Fig. 1 C–F). The remainder
F IGURE 2 Examples of variant histology. (A) Fan type C histology
shows large cells labeling with anti-CD20 in extranodular areas. (B)
Small lymphocytes in nodules of this case label with anti-CD3, identi-
fying typeDNLPHL. (C) CD20 highlights LP cells in theCD20-negative
T-cell background of nodules in type D. (D) This hematoxylin and eosin
(H&E) stain shows an apparently diffuse infiltrate in a case with type
E morphology. (E) This case has >25% with diffuse small lymphocytes
labeling with anti-CD20 as diffuse B-cell type D. This case is not as
“moth-eaten” as usually described. (F) This case labeled with anti-
CD20 shows type Cwith increased extranodular large B cells, merging
into a diffuse type E pattern
showed mixtures of typical and variant histologies. Only categorical
scores of 2 are described in this section unless noted otherwise, since
no scores of 1 showed adverse outcome. The numbers of patients who
have score 2 are as follows: 85 (50.6%) type A, 21 (12.5%) type B, 46
(27.4%) with extranodular large B cells (type C, Fig. 2A), 3 with T-cell-
rich nodular pattern (type D, Figs. 2B and 2C), 55 (32.7%) with diffuse
T-cell-rich (type E, Fig. 2D) pattern, and 2 (1.2%) with diffuse B-cell
moth-eaten pattern (type F, Fig. 2E). There was a total of five patients
(three patients with score 1 and two patients with score 2) with type
F, and these were younger than other patients, 5.0 ± 0.8 and 5.0 ± 0.4
years, respectively, versus12.3±4.0 years for other patients,P=0004.
Type C was associated with decreased EFS (Fig. 3C), as was type D
(Fig. 3D), although there were few patients with D (7 patients
with score 1 and 3 patients with score 2; only score 2 showed
decreased survival). Cases with both types C and E were frequent
(Fig. 2F).
IgD expression was found in LP cells in 65 of 130 tested (50%)
(Fig. 4A), was not associated with outcome, but was positively corre-
lated with types C and E histology (P < 0.0001), and negatively corre-
lated with types A (P= 0.003) and B (P= 0.0059) (Fig. 5).
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F IGURE 3 Survival curves. Kaplan–Meier survival curves for each histologic variant A–F show categorical scores of 0, 1, and 2, with significant
differences seen in type Cwith extranodular LP cells and type D, nodular T-cell-rich type, each showing decreased EFSwith category 2
Seventeen of 168 cases (10.1%) showed CD30 positivity (Fig. 4B).
Of these, 10 had adequate slides for EBV-encoded ribonucleotide
(EBER) in situ hybridization (ISH). One (10% of the CD30+ cases that
were tested) showed EBER positivity in a pattern consistent with
clonal integration. There was no difference in EFS based on CD30
expression.
In sum, variant histology is common in pediatric NLPHL, especially
typesCandE,which are associatedwith IgDexpression. TypeCvariant
histology and possibly type D are associated with decreased EFS, but
neither IgD nor CD30 expression are adverse features. OS could not
be compared since all patients survived.
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F IGURE 4 (A) Extranodular LP cells show cytoplasmic IgD staining
in a background of small T cells in this case that includes score 2 types
C and E, along with score 1 type A; (B) LP cells labels with anti-CD30
F IGURE 5 Categorical scores for each histologic type and for CD30
are compared for IgD expression. Note. Cytoplasmic IgD is negatively
correlated with histologic types A (P= 0.0003) and B (P= 0.0059), and
is positively correlated with types C and E (P< 0.0001).
3 DISCUSSION
NLPHL is an uncommon disease that is frequently indolent and often
cured with chemotherapy and/or RT regimens designed for CHL. Such
treatment, however, poses long-term risks and efforts have beenmade
to reduce therapy in children while preserving good therapeutic out-
comes. This is particularly important in NLPHL, since some patients
have been cured with local therapy such as resection alone. COG pro-
tocol AHOD03P1 tested whether excellent outcomes could be pre-
served in patients with low-risk NLPHL by resection alone or minimal
chemotherapy, and the results appear to be very good.1
Some patients with NLPHL may demonstrate a more aggressive
course than usual, with relapse following therapy or transformation to
B-cell non-Hodgkin lymphoma; thus, efforts have been made to iden-
tify prognostic factors.17,18 Presence or absence of CD30 expression
has been utilized to help distinguish between NLPHL and CHL, varia-
tion in histology has been studied, and IgD expression has also been
examined.6,7,9,16
A few studies have noted that some cases of NLPHL express CD30,
usually in weak and/or focal patterns, and that the morphology and
immunophenotype of these is similar to CD30-negative cases.11,12 A
rare case of relapsed NLPHL with CD30 expression showed response
to brentuximab vedotin, a chimeric anti-CD30 monoclonal antibody
conjugate that is widely used for refractory CHL.15 Huppmann et al.
in a large study of adult and pediatric NLPHL, reported that 3–5%
expressed EBER transcripts and that these more frequently expressed
CD30 than did EBV-negative cases.13 In our current study, only one
CD30-positive case was found to express EBER. CD30-negative cases
were not tested for EBER.
The earliest description of variant histology in lymphocyte predom-
inance Hodgkin lymphoma (LPHL; the accepted term at that time) is
fromDennisWright’s group at Southampton,UK, that studied57 cases
with a panel of monoclonal antibodies in 1989.4 Fifteen cases showed
diffuse histology,most ofwhichwere reclassified asCHL, splenic B-cell
lymphoma, peripheral T-cell lymphoma, or reactive hyperplasia. Four
cases were classified as “diffuse lymphocyte predominance” HL and six
additional cases were categorized as LPHL with indistinct nodularity.
Diffuse cases and cases with indistinct nodularity lacked both CD15
and CD30 and showed polylobated B cells against a background of
small T lymphocytes in the extranodular areas, which was shown
in illustration, and each showed a rim of unstained T lymphocytes
surrounding the polylobated cells on CD20 stain.
The WHO classification of hematopoietic neoplasms, first pub-
lished in 2001 (updated in 2008), added the word “nodular” to the
diagnosis of LPHL and defined NLPHL to require at least a par-
tially nodular pattern.2 In 2003, Fan et al. analyzed 137 samples
from 118 patients with NLPHL and described the six patterns uti-
lized in this study.6 Histologic subtypes overlapped in their study and
there were no cases of pure type C or pure diffuse type E. Our find-
ings are similar in these regards. In their study, 16 cases were pre-
dominantly diffuse while 19 showed a minor component of diffuse
(total = 35). Ten cases showed a predominant pattern of type C and
41 showed presence of a minor component (total = 51). Thus, 43%
showed some type C pattern, compared to 63% of our pediatric cases.
Most samples (127 of 137) showed some component of classic nodu-
lar type A, while 54 showed only type A. Patients with and with-
out recurrence were compared. Samples of those with no recurrence
(n = 27) had median age of 46 years (range 6–91) and a median
follow-up of 20 months. Those patients with recurrence (n = 27) had a
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median ageof 31 (range4–60) andmedian follow-upof 24months.Dif-
fuse pattern, bothpredominant (P=0.001) andpresenceof diffuse (P=
0.003), correlatedwith recurrencebut noother patterndid. Caseswith
multiple specimens showed a trend for cases with type C to develop
diffuse pattern and for caseswith diffuse pattern to relapse as diffused
large B-cell lymphoma (DLBCL; five cases). In some cases, diffuse com-
ponents were not persistent at relapse.
Hartmann et al. studied 423 cases of NLPHL (ages not defined).19
Three hundred fifty (82.7%) had either typical nodular histology (A) or
serpiginous type (B), and 105 (25.4%) had one of the other variants
described by Fan et al. Variants had higher stage, higher international
prognostic index (IPI) score and less5-year progression-free survival (P
= 0.0158), but no difference in overall survival. The authors also found
that low serum albumin and male gender were adverse features, and
described a prognostic scoring systemusing variant histology, albumin,
and gender.
A study by Shankar et al. of pediatric NLPHL also found that vari-
ant histology was associated with higher stage at diagnosis, lower CR
rates, and higher relapse.9 Additionally, IgD expression correlatedwith
poorer treatment response and was more common in patients with
variant histology. That study included 60 patients, all 18 years old or
less, predominantly with stage IIA disease and 6 (10%) with stage IIIA.
Twenty-three percent were treated with surgery alone, 67%with CVP
chemotherapy, and10%withother chemotherapy. Therewas anotably
lower proportion of type C in their study than in our study, with most
variants being diffuse (23% total variant histology).
Compared to our results that found IgD expression in 64 of 130
cases (49%), a study by Prakash et al. identified 27% IgD-positive
patients.16 Median age in that study was 38 years (range 7–81 years).
They demonstrated that IgD expression was associated with younger
age, male predominance, cervical lymph node involvement, and promi-
nent extranodular localization of LP cells (type C). Recently, Hartmann
et al. also evaluated the prognostic role of several additional histo-
logic features in NLPHL and showed no association between IgD and
outcome.7 Seven of eight IgD-positive cases showed type C histology.
Variant histology in NLPHL is currently being included in an updated
revision of theWHOclassification, based on the findings of association
with advanced disease and relapse.20
In our study, the most frequent histologic types were A, B, C, and
E, and all combinations of these (Fig. 2F and Fig. 6). Types C and E
are both associated with cytoplasmic IgD expression. Cases with type
C also tended to show smaller nodules of small B cells compared to
type A. This raises the possibility that cases begin with type A (with
or without B), that the nodules of small B cells regress with devel-
opment of areas of type C, which then further evolve to diffuse type
E. The role of cytoplasmic IgD is unknown, although surface IgD is
attributed to the origin of nodules from the surface of IgD- and IgM-
positive mantle zone cells.3 While the proposed evolution is a conjec-
ture, it was also noted by Fan et al. that there is a tendency for progres-
sion of NLHPL over time to diffuse involvement, that type C may be
an early form of this progression, and that NLPHL and DLBCL may be
related.6 Xing et al. argue that the outcome of NLPHL is largely stage-
related and that therapy usually applied to DLBCL may be optimal for
relapsed NLPHL.21 In their study, relapses of NLPHL included cases
F IGURE 6 Each combination of histologic type seen in the study is
represented, with those containing A, B, C, and E being most common;
other combinations are seen one to three times
of usual DLBCL and also T-cell/histiocyte-rich large B-cell lymphoma,
which resembles the diffuse areas of type E NLPHL. Studies of low-
risk NLPHL in children with long follow-up do not, however, show any
advantage of increased therapy or increased incidence of evolution to
DLBCL.18,22
Our results concur with an emerging trend indicating variant
histology in NLPHL to be more frequent in young people than in
adults, the presence of LP cells in the extranodular T-cell areas (Fan
type C) to be common in young patients, cytoplasmic IgD expression
to be associated with types C and E variant histology. Dim or focal
CD30 expression is not unusual and does not impart adverse risk in
this setting. Variant histology type C with prominent extranodular
large B cells involving > 25% of the sample showed an association
with increased relapse. Type D, with T-cell-rich nodules, also showed
increased relapsewhen>25%but the number of those patients (n= 3)
was too small to draw conclusions. Our study suggests that delineation
of variant histology and performance of IgD staining may be helpful
to identify patients for whom increased surveillance may be indicated,
however, the outcome of the study remains excellent. Overall survival
is 100% and variant histology does not imply that limited therapy is
contraindicated if clinical follow-up is adequate.
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